NUWE Nuwellis, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1506492 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.3%
TTM net income YoY16.9%
TTM EPS YoY197.4%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—
Margins
Gross margin70.8%
Operating margin-135.8%
Net margin-152.8%
FCF margin-136.6%
EBITDA margin-134.2%
Returns
ROE-200.1%
ROA-128.4%
ROIC (approx.)-815.9%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets26.7%
Debt / equity0.00x
Current ratio3.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-13.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $8.27M | $8.74M | $8.86M | $8.54M | $7.92M |
| Cost of revenue | $3.15M | $3.06M | $3.88M | $3.79M | $3.43M |
| Gross profit | $5.12M | $5.68M | $4.98M | $4.75M | $4.49M |
| R&D expense | $2.71M | $3.21M | $5.42M | $4.34M | $4.98M |
| SG&A expense | $13.52M | $13.46M | $17.19M | $17.58M | $19.04M |
| Operating income | -$11.11M | -$10.99M | -$17.63M | -$17.17M | -$19.53M |
| Pretax income | -$17.52M | -$11.16M | -$20.20M | -$14.52M | -$19.55M |
| Income tax | $5,000 | $5,000 | $8,000 | $9,000 | $9,000 |
| Net income | -$17.52M | -$11.16M | -$20.21M | -$14.53M | -$19.55M |
| EBITDA | -$10.91M | -$10.68M | -$17.27M | -$16.80M | -$19.04M |
| EPS (basic) | -25.39 | -353.30 | -360.06 | -83.55 | -285.36 |
| EPS (diluted) | -25.39 | -353.30 | -360.06 | -83.55 | -285.36 |
| Weighted avg. shares (diluted) | 690,145 | 31,601 | 56,126 | 173,846 | 69,000 |
| Balance sheet | |||||
| Cash & equivalents | $1.08M | $5.09M | $3.80M | $17.74M | $8.74M |
| Short-term investments | — | — | $0 | $569,000 | $15.46M |
| Receivables | $1.49M | $1.73M | $1.95M | $1.41M | $750,000 |
| Inventory | $1.91M | $1.72M | $2.00M | $2.66M | $2.84M |
| Current assets | $5.19M | $8.86M | $8.21M | $22.77M | $28.13M |
| PP&E, net | $368,000 | $478,000 | $728,000 | $980,000 | $1.19M |
| Intangibles | $0 | — | — | — | — |
| Total assets | $6.12M | $9.86M | $9.77M | $24.67M | $30.42M |
| Current liabilities | $3.03M | $2.56M | $3.17M | $4.69M | $3.31M |
| Total liabilities | $3.49M | $3.33M | $6.56M | $12.32M | $4.47M |
| Shareholders' equity | $2.62M | $6.53M | $2.99M | $12.36M | $25.95M |
| Shares outstanding | 5,342 | 104,142 | 161,925 | 536,394 | 105,376 |
| Cash flow statement | |||||
| Operating cash flow | -$10.81M | -$9.59M | -$17.94M | -$15.15M | -$17.84M |
| Capital expenditure | $90,000 | $60,000 | $149,000 | $122,000 | $219,000 |
| Free cash flow | -$10.90M | -$9.65M | -$18.09M | -$15.27M | -$18.06M |
| Investing cash flow | -$90,000 | -$60,000 | $330,000 | $14.73M | -$15.72M |
| Financing cash flow | $6.94M | $10.96M | $3.68M | $9.42M | $27.87M |
| Depreciation & amortization | $200,000 | $310,000 | $362,000 | $372,000 | $488,000 |
| Stock-based compensation | $127,000 | $478,000 | $670,000 | $862,000 | $1.31M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.